4D Molecular Therapeutics Inc. has announced positive interim data from its Phase 1/2 PRISM clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD). The interim results, with up to 3.5 years of follow-up, indicate that 4D-150 demonstrated consistent and durable benefits across multiple patient cohorts, including maintenance of visual acuity, control of retinal anatomy, and a reduction in treatment burden. The data also showed a strong dose response in favor of the Phase 3 dose and continued favorable safety, with no new safety or intraocular inflammation findings reported. Detailed results from the PRISM study are scheduled to be presented at an upcoming scientific conference. The company also noted that enrollment in its Phase 3 4FRONT clinical trials is progressing ahead of initial expectations.